We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.37 | -0.92% | 39.64 | 40.005 | 39.49 | 39.97 | 4,916,964 | 01:00:00 |
By Matteo Castia
GlaxoSmithKline PLC said late Wednesday that the European Commission has given conditional marketing authorization to its anti-B-cell maturation antigen therapy belantamab mafodotin.
The British pharmaceuticals giant said belantamab mafodotin has been approved as a monotherapy for the treatment of multiple myeloma in adult patient, in whom the disease was unresponsive to previous treatment.
Earlier this month, the U.S. Food and Drug Administration approved the use of belantamab mafodotin as a monotherapy in the U.S. too.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
August 27, 2020 02:35 ET (06:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions